CN104177456A - 一种阿奇霉素药物原料及制剂和用途 - Google Patents
一种阿奇霉素药物原料及制剂和用途 Download PDFInfo
- Publication number
- CN104177456A CN104177456A CN201310194339.5A CN201310194339A CN104177456A CN 104177456 A CN104177456 A CN 104177456A CN 201310194339 A CN201310194339 A CN 201310194339A CN 104177456 A CN104177456 A CN 104177456A
- Authority
- CN
- China
- Prior art keywords
- impurity
- azythromycin
- azithromycin
- potency
- medicine material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 123
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 122
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 239000002994 raw material Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 229940079593 drug Drugs 0.000 title abstract description 24
- 239000012535 impurity Substances 0.000 claims abstract description 189
- MQTOSJVFKKJCRP-HHZDEWPHSA-N Azythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@H]([C@@]([C@H](O)[C@H](C)N(C)C[C@@H](C)C[C@](C)(O)[C@@H](O[C@@H]2[C@H]([C@@H](C[C@H](C)O2)N(C)C)O)[C@@H]1C)(C)O)CC)[C@@H]1C[C@](C)(OC)[C@H](O)[C@@H](C)O1 MQTOSJVFKKJCRP-HHZDEWPHSA-N 0.000 claims description 89
- 239000007924 injection Substances 0.000 claims description 56
- 238000002347 injection Methods 0.000 claims description 56
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 48
- 239000000463 material Substances 0.000 claims description 43
- 239000000843 powder Substances 0.000 claims description 42
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 29
- 229930064664 L-arginine Natural products 0.000 claims description 29
- 235000014852 L-arginine Nutrition 0.000 claims description 29
- -1 ethyl-2-propyl group Chemical group 0.000 claims description 26
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 claims description 16
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000003978 infusion fluid Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000006188 syrup Substances 0.000 claims description 8
- 235000020357 syrup Nutrition 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 4
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 5
- JBYIGHZCRVMHAK-VINPOOLWSA-N (2r,3r,4s,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-4,10-dihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 JBYIGHZCRVMHAK-VINPOOLWSA-N 0.000 abstract description 2
- PXDYILJJHOVNLO-NZMWSZMZSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound C[C@@]1(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O)[C@H](C)[C@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1 PXDYILJJHOVNLO-NZMWSZMZSA-N 0.000 abstract description 2
- PMJMEZRLHVDXSC-SBXXAWCKSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-2-propyl-1-oxa-6-azacyclopentadecan-15- Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CCC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 PMJMEZRLHVDXSC-SBXXAWCKSA-N 0.000 abstract description 2
- AMNAVVMCWWSBHN-AWHKAWBESA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3s,6r)-3-hydroxy-6-methyl-4-oxooxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H](C(=O)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AMNAVVMCWWSBHN-AWHKAWBESA-N 0.000 abstract description 2
- DEORMZXNPDWMST-BICOPXKESA-N (2s,3r,4s,6r)-2-[[(2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-n,n,6-trimethyloxan-4-amine Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)[N+](C)(C)[O-])O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 DEORMZXNPDWMST-BICOPXKESA-N 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 239000008215 water for injection Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 238000012856 packing Methods 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 9
- 238000005057 refrigeration Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 238000010520 demethylation reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- UNULYJBDEWDIQZ-XVXDYBIPSA-N (1r,4r,4'r,5s,5's,6r,6's,7r,10r,12r,13r,14s,15s,17s)-13-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-4-ethyl-5,5',6,12-tetrahydroxy-4'-methoxy-4',5,6',7,8,10,12,14-octamethylspiro[3,16,18-trioxa-8-azabicyclo[13.4.0]nonadecane-17,2'-oxa Chemical compound C([C@H]1C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@@H](C)[C@@H]1O1)(C)O)CC)O[C@]21C[C@@](C)(OC)[C@@H](O)[C@H](C)O2 UNULYJBDEWDIQZ-XVXDYBIPSA-N 0.000 description 2
- PCDDIDGPAIGEHC-GGNUPITBSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-amino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 PCDDIDGPAIGEHC-GGNUPITBSA-N 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FOKFKPIVUOKMAB-KRYDKTARSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-14-(hydroxymethyl)-3,5,6,8,10,12-hexamethyl-1-oxa-6-azacyclo Chemical compound O([C@@H]1[C@@H](CO)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 FOKFKPIVUOKMAB-KRYDKTARSA-N 0.000 description 1
- HRKNNHYKWGYTEN-HOQMJRDDSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)NC[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 HRKNNHYKWGYTEN-HOQMJRDDSA-N 0.000 description 1
- PAIIKRKARNTWPY-HOQMJRDDSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-13-[(2r,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 PAIIKRKARNTWPY-HOQMJRDDSA-N 0.000 description 1
- FZYUKBLYECHAGN-HOQMJRDDSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3r,4s,6r)-3-hydroxy-6-methyl-4-(methylamino)oxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@@H](NC)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 FZYUKBLYECHAGN-HOQMJRDDSA-N 0.000 description 1
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 description 1
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000219422 Urtica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- PAZSFKCLSYSRGC-XOZZEHTCSA-N n-[(2s,3r,4s,6r)-2-[[(2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-n,4-di Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)S(=O)(=O)C=2C=CC(C)=CC=2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 PAZSFKCLSYSRGC-XOZZEHTCSA-N 0.000 description 1
- QNGDWLRYIAHQGP-BICOPXKESA-N n-[(2s,3r,4s,6r)-2-[[(2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-n-meth Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C=O)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 QNGDWLRYIAHQGP-BICOPXKESA-N 0.000 description 1
- FSUFNIVRKKVCSI-HOQMJRDDSA-N n-[(2s,3r,4s,6r)-2-[[(2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]formami Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@@H](NC=O)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 FSUFNIVRKKVCSI-HOQMJRDDSA-N 0.000 description 1
- UXWVLGKGQGGAID-SYARVETMSA-N n-[4-[[(2s,3r,4s,6r)-2-[[(2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-me Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)S(=O)(=O)C=2C=CC(NC(C)=O)=CC=2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 UXWVLGKGQGGAID-SYARVETMSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 238000011137 process chromatography Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
时间(分钟) | 流动相A% | 流动相B% |
0~25 | 50→45 | 50→55 |
25~30 | 45→40 | 55→60 |
30~80 | 40→25 | 60→75 |
80~81 | 25→50 | 75→50 |
81~93 | 50 | 50 |
杂质 | 英文简写 | 中文名 |
A | 6-demethylazithromycin | 6-脱甲基阿奇霉素 |
B | 3-deoxyazithromycin | 3-脱氧阿奇霉素 |
C | 3″-O-demethylazithromycin | 3″-O-脱甲基阿奇霉素 |
D | 14-demethyl-14-(hydroxymethyl)azithromycin (azithromycinF) | 14-脱甲基-14-羟甲基阿奇霉素(阿奇霉素F) |
E | 3'-(N,N-didemethyl)azithromycin(aminoazithromycin) | 3'-(N,N-脱二甲基)阿奇霉素(氨基阿奇霉素) |
F | 3'-N-demethyl-3'-N-formylazithromycin | 3'-N-脱甲基-3'-N-甲酰基阿奇霉素 |
G | 3'-N-demethyl-3'-N-[(4-methylphenyl)sulfonyl]azithromycin | 3'-N-脱甲基-3'-N-[(4-甲基苯基)磺酰基]阿奇霉素 |
H | 3'-N-[[4-(acetylamino)phenyl]sulfonyl]-3'-N-demethylazithromycin | 3'-N-[[4-(乙酰氨基)苯基]磺酰基]-3'-N-脱甲基阿奇霉素 |
I | 3′-N-demethylazithromycin | 3'-N-脱甲基阿奇霉素 |
J | 13-O-decladinosylazithromycin | 13-O-脱克拉定塘阿奇霉素 |
K | C 14,1″-epoxyazithromycin(azithromycin E) | C 14,1″-环氧基阿奇霉素(阿奇霉素E) |
L | azithromycin 3′-N-oxide | 阿奇霉素3'-N-氧化物 |
M | 3'-(N,N-didemethyl)-3'-N-formylazithromycin | 3'-(N,N-脱二甲基)-3'-N-甲酰基阿奇霉素 |
N | 3'-de(dimethylamino)-3'-oxoazithromycin | 3'-脱(二甲氨基)-3'-氧代阿奇霉素 |
O | 2-desethyl-2-propylazithromycin | 2-脱乙基-2-丙基阿奇霉素 |
P | 未知 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310194339.5A CN104177456B (zh) | 2013-05-23 | 2013-05-23 | 一种阿奇霉素药物原料及制剂和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310194339.5A CN104177456B (zh) | 2013-05-23 | 2013-05-23 | 一种阿奇霉素药物原料及制剂和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104177456A true CN104177456A (zh) | 2014-12-03 |
CN104177456B CN104177456B (zh) | 2016-07-13 |
Family
ID=51958828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310194339.5A Active CN104177456B (zh) | 2013-05-23 | 2013-05-23 | 一种阿奇霉素药物原料及制剂和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104177456B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101445532A (zh) * | 2008-12-30 | 2009-06-03 | 广东东阳光药业有限公司 | 阿奇霉素一水合物结晶的制备方法 |
WO2011015219A1 (en) * | 2009-08-06 | 2011-02-10 | Shifa Pharmed Industrial Group Co. | Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers |
CN102911219A (zh) * | 2011-08-03 | 2013-02-06 | 山东方明药业集团股份有限公司 | 一种阿齐霉素在水相直接结晶的方法 |
PL397204A1 (pl) * | 2011-12-01 | 2013-06-10 | Tarchominskie Zaklady Farmaceutyczne "Polfa" Spólka Akcyjna | Sposób syntezy i izolacji des azytromycyny |
-
2013
- 2013-05-23 CN CN201310194339.5A patent/CN104177456B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101445532A (zh) * | 2008-12-30 | 2009-06-03 | 广东东阳光药业有限公司 | 阿奇霉素一水合物结晶的制备方法 |
WO2011015219A1 (en) * | 2009-08-06 | 2011-02-10 | Shifa Pharmed Industrial Group Co. | Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers |
CN102911219A (zh) * | 2011-08-03 | 2013-02-06 | 山东方明药业集团股份有限公司 | 一种阿齐霉素在水相直接结晶的方法 |
PL397204A1 (pl) * | 2011-12-01 | 2013-06-10 | Tarchominskie Zaklady Farmaceutyczne "Polfa" Spólka Akcyjna | Sposób syntezy i izolacji des azytromycyny |
Also Published As
Publication number | Publication date |
---|---|
CN104177456B (zh) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101185692B (zh) | 一种胆木提取物及其制剂与用途 | |
ES2754614T3 (es) | Forma cristalina de levoisovalerilespiramicina II y preparaciones, procedimientos de preparación y utilizaciones de la misma | |
CN101919961B (zh) | 一种治疗感冒的药物组合物及其制备方法 | |
CN102247396A (zh) | 左旋可利霉素、其药物组合物、制备方法及应用 | |
CN101274025A (zh) | 一种具有清热泻火解毒作用的中药组合物及其制备方法和质量控制方法 | |
CN103070912A (zh) | 一种苦参总黄酮提取物及其制备方法、质量检测方法 | |
CN103417512B (zh) | 一种阿莫西林胶囊剂及其制备方法 | |
CN101912368A (zh) | 一种复方头孢克洛干混悬剂及其制备方法 | |
CN102961469A (zh) | 一种治疗上呼吸道感染的中药分散片及其制备和质量检测方法 | |
CN101003540A (zh) | 一种抗感染化合物和用途 | |
CN107224577A (zh) | 一种基于3型肺炎链球菌荚膜多糖的寡糖缀合物及其制备方法与应用 | |
CN104177456A (zh) | 一种阿奇霉素药物原料及制剂和用途 | |
CN104095809A (zh) | 克林霉素磷酸酯注射液药物组合物和制法 | |
CN101623284A (zh) | 一种复方维生素c注射剂药物组合物 | |
CN104177457A (zh) | 一种阿奇霉素药物原料及其制剂和用途 | |
CN103622916B (zh) | 一种头孢克肟干混悬制剂及其制备方法 | |
Saptarini et al. | Stability studies of Amoxicillin and gentamicin injection in intravenous infusions | |
CN104974239A (zh) | 一种离子交换和反相层析结合分离纯化眼镜蛇毒神经毒素的方法 | |
CN101125871A (zh) | 硫酸阿奇霉素和其应用及其冻干粉针剂和冻干粉针剂的制备方法 | |
CN1772089B (zh) | 一种含有白花蛇舌草冻干粉针剂及其制备方法 | |
CN102657618A (zh) | 一种阿奇霉素颗粒及其制备方法 | |
CN101348514B (zh) | 一种从面包海星提取的海星皂苷类化合物的用途 | |
CN102432646B (zh) | 一种庆大霉素C1a衍生物及其提取分离方法 | |
CN111189938B (zh) | 猪血浆及肺泡液内艾地普林和磺胺甲噁唑的定量检测方法 | |
CN104177458A (zh) | 一种阿奇霉素药物原料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Patentee after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Patentee before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug raw material and preparation of azithromycin, and its use Effective date of registration: 20231226 Granted publication date: 20160713 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000146 |